Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


GUGGENHIME ANDREW Create: Alert

All | News | Filings
Date FiledTypeDescription
02/23/2023 4 GUGGENHIME ANDREW (Director) has filed a Form 4 on Caribou Biosciences, Inc.
Txns: Granted 21,500 options to buy @ $6.12, valued at $131.6k
01/04/2023 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Granted 42,000 options to buy @ $47.95, valued at $2M
Exercised 23,691 options to buy @ $5.35, valued at $126.7k
09/21/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 2,623 shares @ $26.019, valued at $68.2k
Sold 477 shares @ $26.52, valued at $12.7k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
09/07/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Paid exercise price by delivering 4,649 shares @ $26.38, valued at $122.6k
09/06/2022 4 GUGGENHIME ANDREW (Director) has filed a Form 4 on Metacrine, Inc.
Txns: Granted 16,500 options to buy @ $0.42, valued at $6.9k
08/29/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 17,052 shares @ $28, valued at $477.5k
Sold 1,295 shares @ $28, valued at $36.3k
Sold 17,653 shares @ $28, valued at $494.3k
Exercised 17,052 options to buy @ $5.35, valued at $91.2k
Exercised 1,295 options to buy @ $5.35, valued at $6.9k
Exercised 17,653 options to buy @ $5.35, valued at $94.4k
08/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 3,091 shares @ $24.53, valued at $75.8k
Sold 9 shares @ $25, valued at $225
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
07/12/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 3,100 shares @ $24, valued at $74.4k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
05/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 3,100 shares @ $24.0459, valued at $74.5k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
03/22/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 3,100 shares @ $26.1267, valued at $81k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
03/04/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Granted 37,500 shares @ $0
Granted 225,000 options to buy @ $24.79, valued at $5.6M
03/03/2022 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 6,200 shares @ $24, valued at $148.8k
Exercised 6,200 options to buy @ $5.35, valued at $33.2k
12/28/2021 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 3,100 shares @ $24, valued at $74.4k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
12/21/2021 4 GUGGENHIME ANDREW (Director) has filed a Form 4 on Caribou Biosciences, Inc.
Txns: Granted 27,500 options to buy @ $15.16, valued at $416.9k
11/22/2021 4 GUGGENHIME ANDREW (President and CFO) has filed a Form 4 on Vaxcyte, Inc.
Txns: Sold 2,985 shares @ $24.5, valued at $73.1k
Sold 115 shares @ $25.2, valued at $2.9k
Exercised 3,100 options to buy @ $5.35, valued at $16.6k
07/22/2021 3 GUGGENHIME ANDREW (Director) has filed a Form 3 on Caribou Biosciences, Inc.
05/25/2021 4 GUGGENHIME ANDREW (Director) has filed a Form 4 on Metacrine, Inc.
Txns: Granted 16,500 options to buy @ $4.07, valued at $67.2k
04/06/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/15/2020 3 GUGGENHIME ANDREW (Director) has filed a Form 3 on Metacrine, Inc.
06/11/2020 3 GUGGENHIME ANDREW (CFO, CBO) has filed a Form 3 on Vaxcyte, Inc.
02/24/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/19/2019 4 GUGGENHIME ANDREW (CFO) has filed a Form 4 on Dermira, Inc.
Txns: Paid exercise price by delivering 986 shares @ $7.91, valued at $7.8k
Paid exercise price by delivering 1,233 shares @ $7.91, valued at $9.8k
Paid exercise price by delivering 1,232 shares @ $7.91, valued at $9.7k
Exercised 3,563 restricted stock units @ $0
Exercised 2,850 restricted stock units @ $0
Exercised 3,562 restricted stock units @ $0
05/21/2019 4 GUGGENHIME ANDREW (CFO) has filed a Form 4 on Dermira, Inc.
Txns: Paid exercise price by delivering 8,645 shares @ $10.5, valued at $90.8k
Exercised 25,000 restricted stock units @ $0
02/14/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2018 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
Txns: Paid exercise price by delivering 329 shares @ $9.58, valued at $3.2k
Paid exercise price by delivering 1,232 shares @ $9.58, valued at $11.8k
Paid exercise price by delivering 1,233 shares @ $9.58, valued at $11.8k
Granted 50,000 restricted stock units @ $0
Exercised 950 restricted stock units @ $0
Exercised 3,562 restricted stock units @ $0
Exercised 3,563 restricted stock units @ $0
02/16/2018 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
Txns: Granted 57,000 options to buy @ $28.25, valued at $1.6M
Granted 9,500 restricted stock units @ $0
08/17/2017 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
Txns: Paid exercise price by delivering 1,339 shares @ $23.58, valued at $31.6k
Paid exercise price by delivering 447 shares @ $23.58, valued at $10.5k
Exercised 1,188 restricted stock units @ $0
Exercised 3,562 restricted stock units @ $0
02/22/2017 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
11/10/2016 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
10/13/2016 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
09/20/2016 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
09/14/2016 4 GUGGENHIME ANDREW (COO and CFO) has filed a Form 4 on Dermira, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy